An overview of up-and-coming immune checkpoint inhibitors for pancreatic cancer.

Himil MahadeviaPedro Luiz Serrano Uson JuniorJing WangMitesh BoradHani Babiker

Published in: Expert opinion on pharmacotherapy (2024)

Studies evaluating different drugs to transform the tumor microenvironment (TME) from 'cold' to 'hot' have not shown promise in PC. There still needs to be more prospective trials evaluating the efficacy of the combination of ICIs with different therapeutic modalities in PC that can augment the immunogenic potential of those 'cold' tumors. Exploratory biomarker analysis may help us identify those subsets of PC patients who may particularly benefit from ICIs.

Keyphrases

peripheral blood
big data
machine learning
human health
case control
climate change
artificial intelligence
data analysis